- Home
- ERNA vs ALLR Comparison
ERNA vs ALLR Comparison
Compare ERNA & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERNA
- ALLR
- Stock Information
- Founded
- ERNA 2018
- ALLR 2004
- Country
- ERNA United States
- ALLR United States
- Employees
- ERNA N/A
- ALLR N/A
- Industry
- ERNA Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- ERNA Health Care
- ALLR Health Care
- Exchange
- ERNA Nasdaq
- ALLR Nasdaq
- Market Cap
- ERNA 13.5M
- ALLR 15.8M
- IPO Year
- ERNA N/A
- ALLR N/A
- Fundamental
- Price
- ERNA $1.92
- ALLR $1.01
- Analyst Decision
- ERNA
- ALLR
- Analyst Count
- ERNA 0
- ALLR 0
- Target Price
- ERNA N/A
- ALLR N/A
- AVG Volume (30 Days)
- ERNA 53.7K
- ALLR 416.0K
- Earning Date
- ERNA 08-12-2025
- ALLR 08-04-2025
- Dividend Yield
- ERNA N/A
- ALLR N/A
- EPS Growth
- ERNA N/A
- ALLR N/A
- EPS
- ERNA N/A
- ALLR N/A
- Revenue
- ERNA $535,000.00
- ALLR N/A
- Revenue This Year
- ERNA N/A
- ALLR N/A
- Revenue Next Year
- ERNA N/A
- ALLR N/A
- P/E Ratio
- ERNA N/A
- ALLR N/A
- Revenue Growth
- ERNA 365.22
- ALLR N/A
- 52 Week Low
- ERNA $1.75
- ALLR $0.61
- 52 Week High
- ERNA $32.40
- ALLR $7.38
- Technical
- Relative Strength Index (RSI)
- ERNA 39.97
- ALLR 49.71
- Support Level
- ERNA $1.91
- ALLR $0.95
- Resistance Level
- ERNA $2.57
- ALLR $1.14
- Average True Range (ATR)
- ERNA 0.18
- ALLR 0.07
- MACD
- ERNA 0.04
- ALLR -0.00
- Stochastic Oscillator
- ERNA 19.77
- ALLR 26.26
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.